分析重组人血管内皮抑制素注射液联合化疗治疗中晚期非小细胞肺癌的临床疗效  

Analysis of the Clinical Efficacy of Recombinant Human Vascular Endothelial Inhibitor Injection Combined with Chemotherapy in the Treatment of Intermediate and Advanced Non-small Cell Lung Cancer

作　　者：尹彦海 李新 王孟 马志英[2] 赵娜[2] YIN Yanhai;LI Xin;WANG Meng;MA Zhiying;ZHAO Na(Department of Oncology,Binzhou Central Hospital,Binzhou,Shandong Province,251700 China;Department ofRespiratory Medicine,Binzhou Central Hospital,Binzhou,Shandong Province,251700 China)

机构地区：[1]滨州市中心医院肿瘤科,山东滨州251700 [2]滨州市中心医院呼吸内科,山东滨州251700

出　　处：《中外医疗》2024年第2期97-101,共5页China & Foreign Medical Treatment

摘　　要：目的分析重组人血管内皮抑制素注射液联合化疗治疗中晚期非小细胞肺癌的临床疗效。方法随机选取2019年1月—2023年1月滨州市中心医院收治的中晚期非小细胞肺癌患者80例为研究对象,随机数表法分为对照组(n=40,单纯化疗治疗)和研究组(n=40,重组人血管内皮抑制素注射液联合化疗治疗)。比较两组患者近期临床疗效、治疗前后的血清鳞状上皮细胞癌抗原(Squamous Cell Carcinoma Antigen,SCC)、癌胚抗原(Carcinoembryonic Antigen,CEA)、细胞角蛋白19片段(Cytokeratin 19 Fragments,CYFRA21-1)水平、症状评分改善情况、不良反应发生情况。结果研究组客观缓解率(20.0%)、疾病控制率(85.0%)均明显高于对照组5.0%、65.0%,差异有统计学意义(χ^(2)=4.114、4.267,P均<0.05)。治疗后,研究组血清SCC、CEA、CYFRA21-1水平、症状评分均优于对照组,差异有统计学意义(P均<0.05)。两组患者不良反应发生情况比较,差异无统计学意义(P>0.05)。结论分析重组人血管内皮抑制素注射液联合化疗治疗中晚期非小细胞肺癌具有良好的疗效,并显著优于单纯化疗治疗。Objective To analyze the clinical efficacy of recombinant human vascular endothelial inhibitor injection combined with chemotherapy in the treatment of intermediate and advanced non-small cell lung cancer.Methods A total of 80 patients with advanced non-small cell lung cancer treated in Binzhou Central Hospital from January 2019 to January 2023 were randomly selected as the study objects,and randomly divided into control group(n=40,chemotherapy alone)and study group(n=40,recombinant human endostatin injection combined with chemotherapy)according to random nember table method.Compared the recent clinical efficacy,serum squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA),cytokeratin 19 fragments(CYFRA21-1)levels,symptom score improvement,and incidence of adverse reactions between two groups of patients before and after treatment.Results The objective remission rate(20.0%)and disease control rate(85.0%)of the study group were significantly higher than those of the control group(5.0%and 65.0%),and the differences were statistically significant(χ^(2)=4.114,4.267,both P<0.05).After treatment,the serum levels of SCC,CEA,CYFRA21-1 and symptom score of the study group were better than those of the control group,and the differences were statistically significant(all P<0.05).There was no statistically significant difference in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion Analysis Recombinant human endostatin injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer has a good effect,and is significantly better than chemotherapy alone.

关 键 词：重组人血管内皮抑制素注射液 化疗 中晚期非小细胞肺癌 临床疗效 

分 类 号：R73[医药卫生—肿瘤]